A definition and classification of status epilepticus – Report of the ILAE Task Force on Classification of Status Epilepticus
2015/09/04 by Eugen Trinka, Hannah Cock, Hannah R. Cock +7 · 49 citations
Medicine · Neuroscience · #Epilepsy research and treatment #Neuroscience and Neuropharmacology Research #Pharmacological Effects and Toxicity Studies
paper · doi:10.1111/epi.13121
Abstract
The Commission on Classification and Terminology and the Commission on Epidemiology of the International League Against Epilepsy (ILAE) have charged a Task Force to revise concepts, definition, and classification of status epilepticus (SE). The proposed new definition of SE is as follows: Status epilepticus is a condition resulting either from the failure of the mechanisms responsible for seizure termination or from the initiation of mechanisms, which lead to abnormally, prolonged seizures (after time point t1 ). It is a condition, which can have long-term consequences (after time point t2 ), including neuronal death, neuronal injury, and alteration of neuronal networks, depending on the type and duration of seizures. This definition is conceptual, with two operational dimensions: the first is the length of the seizure and the time point (t1 ) beyond which the seizure should be regarded as "continuous seizure activity." The second time point (t2 ) is the time of ongoing seizure activity after which there is a risk of long-term consequences. In the case of convulsive (tonic-clonic) SE, both time points (t1 at 5 min and t2 at 30 min) are based on animal experiments and clinical research. This evidence is incomplete, and there is furthermore considerable variation, so these time points should be considered as the best estimates currently available. Data are not yet available for other forms of SE, but as knowledge and understanding increase, time points can be defined for specific forms of SE based on scientific evidence and incorporated into the definition, without changing the underlying concepts. A new diagnostic classification system of SE is proposed, which will provide a framework for clinical diagnosis, investigation, and therapeutic approaches for each patient. There are four axes: (1) semiology; (2) etiology; (3) electroencephalography (EEG) correlates; and (4) age. Axis 1 (semiology) lists different forms of SE divided into those with prominent motor systems, those without prominent motor systems, and currently indeterminate conditions (such as acute confusional states with epileptiform EEG patterns). Axis 2 (etiology) is divided into subcategories of known and unknown causes. Axis 3 (EEG correlates) adopts the latest recommendations by consensus panels to use the following descriptors for the EEG: name of pattern, morphology, location, time-related features, modulation, and effect of intervention. Finally, axis 4 divides age groups into neonatal, infancy, childhood, adolescent and adulthood, and elderly.
Citations
Cited by
- Acute symptomatic status epilepticus: Splitting or lumping? A proposal of classification based on real‐world data
- Clinical practice guidelines on the management of status epilepticus in adults: A systematic review
- Prognostic factors and impact of management strategies for status epilepticus: The STEPPER study in the Emilia‐Romagna region, Italy
- Response of early status epilepticus to benzodiazepines in chronic benzodiazepine users: A case–control study
- Treatment adequacy outweighs treatment sequence in non‐convulsive status epilepticus
- Emergency treatment delay and underdosing are associated with poor outcome in non‐convulsive status epilepticus
- Association of Peri-ictal MRI Abnormalities With Mortality, Antiseizure Medication Refractoriness, and Morbidity in Status Epilepticus
- Updated classification of epileptic seizures: Position paper of the International League Against Epilepsy
- Myoclonus After Cardiac Arrest: Need for Standardization—A Systematic Review and Research Proposal on Terminology
- The Human Phenotype Ontology in 2021
- Misdiagnosis of prolonged psychogenic non-epileptic seizures as status epilepticus: epidemiology and associated risks
- Focal hypermetabolism in suspected non‐convulsive status epilepticus
- Evaluating Levetiracetam Weight-Based Dosing in Benzodiazepine-Refractory Status Epilepticus
- Incidence, mortality, and management of status epilepticus from 2012 to 2022: An 11‐year nationwide study
- Cannabidiol Pretreatment Reduces Status Epilepticus and Glutamate Uptake Induced by Kainic Acid in Adult Zebrafish
- Efficacy of phenobarbital is maintained after exposure to mild‐to‐moderate seizures in neonates
- Nonconvulsive status epilepticus in patients under intensive care: Should we view epilepsy as a sleep disorder?
- Dreams interrupted: characteristics of REM sleep–associated seizures and status epilepticus
- Time to genetic testing in Dravet syndrome: Trends, barriers, and opportunities for improvement
- Status epilepticus: Updates on mechanisms and treatments
- Incidence and prehospital management of convulsive status epilepticus in Martinique, a French Caribbean territory
- Extracellular vesicle proteomics identifies novel blood biomarkers for the early diagnosis of status epilepticus
- The impact of revised definitions on the epidemiology of status epilepticus: A population‐based study
- Optimizing phenobarbital dosing in critically ill patients with refractory and superrefractory status epilepticus using a population pharmacokinetic model
- Pharmacotherapy for Status Epilepticus. [europepmc]
- Immunity and inflammation in status epilepticus and its sequelae: possibilities for therapeutic application. [europepmc]
- Recent advances in epilepsy. [europepmc]
- Cerebrospinal fluid microRNAs are potential biomarkers of temporal lobe epilepsy and status epilepticus. [europepmc]
- Timing is everything: Where status epilepticus treatment fails. [europepmc]
- Status Epilepticus: Behavioral and Electroencephalography Seizure Correlates in Kainate Experimental Models. [europepmc]
- Acute and long-term consequences of exposure to organophosphate nerve agents in humans. [europepmc]
- Epidemiology of status epilepticus in adults: A population-based study on incidence, causes, and outcomes. [europepmc]
- Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models. [europepmc]
- Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABA B R encephalitis. [europepmc]
- Change in Mortality of Generalized Convulsive Status Epilepticus in High-Income Countries Over Time: A Systematic Review and Meta-analysis. [europepmc]
- Excitatory GABAergic signalling is associated with benzodiazepine resistance in status epilepticus. [europepmc]
- Treatment of Refractory Convulsive Status Epilepticus: A Comprehensive Review by the American Epilepsy Society Treatments Committee. [europepmc]
- Ketamine to treat super-refractory status epilepticus. [europepmc]
- Central Nervous System Manifestations Associated with COVID-19. [europepmc]
- The Human Phenotype Ontology in 2021. [europepmc]
- American Clinical Neurophysiology Society's Standardized Critical Care EEG Terminology: 2021 Version. [europepmc]
- Soft implantable drug delivery device integrated wirelessly with wearable devices to treat fatal seizures. [europepmc]
- The Kainic Acid Models of Temporal Lobe Epilepsy. [europepmc]
- Nanotherapeutics for Nose-to-Brain Drug Delivery: An Approach to Bypass the Blood Brain Barrier. [europepmc]
- Levetiracetam Mechanisms of Action: From Molecules to Systems. [europepmc]
- Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability. [europepmc]
- Rates of Status Epilepticus and Sudden Unexplained Death in Epilepsy in People With Genetic Developmental and Epileptic Encephalopathies. [europepmc]
- Guidelines for Neuroprognostication in Comatose Adult Survivors of Cardiac Arrest. [europepmc]
- Updated classification of epileptic seizures: Position paper of the International League Against Epilepsy. [europepmc]
Related